Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Conditions: Zika; Zika Virus Infection Interventions: Biological: VLA1601; Biological: CpG 1018 ®; Biological: 3M-052-AF Sponsors: Valneva Austria GmbH Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials